CoChat

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy

Open access
McKenzie, Jodi A, Mbofung, Rina M, Malu, Shruti, Zhang, Min, Ashkin, Emily, Devi, Seram, Williams, Leila, Tieu, Trang, Peng, Weiyi, Pradeep, Sunila, Xu, Chunyu, Zorro Manrique, Soraya, Liu, Chengwen, Huang, Lu, Chen, Yuan, Forget, Marie-Andree, Haymaker, Cara, Bernatchez, Chantale, Satani, Nikunj, Muller, Florian, Roszik, Jason, Kalra, Ashish, Heffernan, Timothy, Sood, Anil, Hu, Jianhua, Amaria, Rodabe, Davis, R Eric, Hwu, Patrick · 2018 · JNCI: Journal of the National Cancer Institute
Cited by 91

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: Immunotherapy has increasingly become a staple in cancer treatment. However, substantial limitations in the durability of response highlight the need for more rational therapeutic combinations. The aim of this study is to investigate how to make tumor cells more sensitive to T-cell-based cancer immunotherapy. Methods: Two pairs of melanoma patient-derived tumor cell lines and their autologous tumor-infiltrating lymphocytes were utilized in a high-throughput screen of 850 compounds to identify bioactive agents that could be used in combinatorial strategies to improve T-cell-mediated killing of tumor cells. RNAi, overexpression, and gene expression analyses were utilized to identify the mechanism underlying the effect of Topoisomerase I (Top1) inhibitors on T-cell-mediated killing. Using a syngeneic mouse model (n = 5 per group), the antitumor efficacy of the combination of a clinically relevant Top1 inhibitor, liposomal irinotecan (MM-398), with immune checkpoint inhibitors was also assessed. All statistical tests were two-sided. Results: We found that Top1 inhibitors increased the sensitivity of patient-derived melanoma cell lines (n = 7) to T-cell-mediated cytotoxicity (P < .001, Dunnett's test). This enhancement is mediated by TP53INP1, whose overexpression increased the susceptibility of melanoma cell lines to T-cell cytotoxicity (2549 cell line: P = .009, unpaired t test), whereas its knockdown impeded T-cell killing of Top1 inhibitor-treated melanoma cells (2549 cell line: P < .001, unpaired t test). In vivo, greater tumor control was achieved with MM-398 in combination with α-PD-L1 or α-PD1 (P < .001, Tukey's test). Prolonged survival was also observed in tumor-bearing mice treated with MM-398 in combination with α-PD-L1 (P = .002, log-rank test) or α-PD1 (P = .008, log-rank test). Conclusions: We demonstrated that Top1 inhibitors can improve the antitumor efficacy of cancer immunotherapy, thus providing the basis for developing novel strategies using Top1 inhibitors to augment the efficacy of immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djx257

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 91

Metadata

Authors
McKenzie, J. A., Mbofung, R. M., Malu, S., Zhang, M., Ashkin, E., Devi, S., Williams, L., Tieu, T., Peng, W., Pradeep, S., Xu, C., Zorro Manrique, S., Liu, C., Huang, L., Chen, Y., Forget, M.-A., Haymaker, C., Bernatchez, C., Satani, N., Muller, F., Roszik, J., Kalra, A., Heffernan, T., Sood, A., Hu, J., Amaria, R., Davis, R. E., & Hwu, P.
Venue
JNCI: Journal of the National Cancer Institute
Published
2017-12-18
Volume
110
Issue
7
Pages
777-786
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2776126183
Cited by
91
References
15
FWCI
2.48
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. https://app.cochat.ai/papers/10.1093/jnci/djx257
The paper
McKenzie, J. A., Mbofung, R. M., Malu, S., Zhang, M., Ashkin, E., Devi, S., Williams, L., Tieu, T., Peng, W., Pradeep, S., Xu, C., Zorro Manrique, S., Liu, C., Huang, L., Chen, Y., Forget, M.-A., Haymaker, C., Bernatchez, C., Satani, N., . . . Hwu, P. (2018). The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djx257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.